Akari Therapeutics, PLC

75/76 Wimpole Street

London W1G 9RT

United Kingdom


  April 14, 2020


Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549


Re: Akari Therapeutics, PLC

Registration Statement on Form F-3

File No. 333-237389




Ladies and Gentlemen:


Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, PLC (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-3 (File No. 333-237389) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on April 16, 2020 or as soon thereafter as may be practicable.


The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery LLP, by calling Gary Emmanuel at (212) 547-5541. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.











  Very truly yours,  
  By: /s/ Clive Richardson  
  Name: Clive Richardson  
  Title:    Chief Executive Officer and Chief  Operating Officer